Navin Jacob

Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...

Gilead Sciences, Inc. (NASDAQ: GILD) reported an earnings and sales beat Thursday, but apprehension surrounding the drugmaker's remdesivir, under evaluation as a potential COVID-19 treatment, are weighing down on the stock. The Gilead Analysts Wells Fargo Securities analyst Jim...

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares have been under pressure since mid-May, when it was accused along with other generic companies for inflating the prices of generic drugs. The Israeli drugmaker announced an $85-million settlement agreement Tuesday with the state of...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced additional positive data from its pivotal Phase 3 REGENERATE trial Wednesday. The trial is evaluating Intercept's obeticholic acid, or OCA, in patients with liver fibrosis due to non-alcoholic steatohepatitis, or NASH. The new data...

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) stock is down 73 percent from its 2015 peak — and it's nearly struck bottom, with recovery just around the corner, in UBS' view.  The Analyst Analyst Navin Jacob upgraded Teva from Neutral to Buy and raised the price target...